QRL Bioscience develops personalised, living cell-based therapies aimed at treating chronic degenerative conditions, with initial programs for diabetic foot ulcers (DFU) and osteoarthritis. The company has advanced clinical groundwork for its DFU therapy and achieved key research milestones on its osteoarthritis program. Founders Dr Senthilkumar Natesan, Sanjoy Bhagat, and Dr Kranti Vora bring scientific, clinical, and commercial expertise to the venture. Current plans focus on accelerating the DFU therapy through clinical trials and advancing the osteoarthritis treatment through preclinical and formulation work. QRL has built supply-chain capacity, engaged medical professionals, and identified distribution channels as part of its commercial strategy. The company intends to use new funds to move products toward market readiness and pursue co-development and co-marketing partnerships in the orthopaedic sector.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2025